演題詳細

ポスター / Poster

ポスター 23 (Poster 23) :低悪性度B細胞リンパ腫:ベンダムスチン

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
瀧本 理修 (Rishu Takimoto):1
1:札幌医科大学医学部附属病院 腫瘍・血液内科
 
前へ戻る

Efficacy of bendamustine for relapsed/refractory indolent B-cell lymphomas: Single center experience

演題番号 : PS-1-172

市川 喜一 (Yoshikazu Ichikawa):1、中山 豊 (Yutaka Nakayama):1、菅沢 邦江 (Kunie Sugasawa):2、山下 鷹也 (Takaya Yamashita):4、廣川 誠 (Makoto Hirokawa):3、澤田 賢一 (Kenichi Sawada):4

1:Department of Hematology and Nephrology, Akita City Hospital, Akita, Japan、2:Department of Hematology, Nihonkai General Hospital, Sakata, Japan、3:Clinical Oncology Center, Akita University Hospital, Akita, Japan、4:Hematology, Nephrology and Rheumatology, Akita University, Akita, Japan

 

Introduction: We retrospectively evaluated the efficacy and toxicity of bendamustine in patients with relapsed or refractory indolent B-cell lymphomas. Patients and Treatment: This study was designed as a retrospective cohort study and was approved by the institutional review board. Between December 2010 and March 2013, 8 patients with follicular lymphoma (FL) and 2 patients with mantle cell lymphoma (MCL) received bendamustine. The median age was 69 years (range, 45-80), and 50% were male. The median numbers of prior regimens was 2 (1-4). One patient received bendamustine alone 120mg/m2 on days 1 and 2 every 3 weeks (B), 6 patients received rituximab 375mg/m2 on days 1 and bendamustine 90mg/m2 on days 2 and 3 every 4 weeks (BR). Two patients switched BR to B within 2 cycles, and other 1 patient switched B to BR after 5 cycles. Three patients are still receiving treatment now. All patients received ST and acycrovir for prevention of infection, and 1 patient with HBV received entecavir. Result: Among 7 patients who completed treatment, the clinical response was observed in 5 patients (71%), including 1CR, 3CRu and 1PR. Grade3/4 lymphocytopenia occurred in all patients, and leukocytopenia in 71%. Nonhematologic adverse events included anorexia, nausea, fatigue and dysgeusia. All adverse events were recovered. There was no treatment related death. Conclusion: Bendamustine treatment is high efficacy and tolerable regimen in patients with relapsed or refractory indolent B-cell lymphomas.

前へ戻る